Published in Kidney Int on April 01, 2017
Structural and Functional Changes in Human Kidneys with Healthy Aging. J Am Soc Nephrol (2017) 0.75
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature (2006) 9.30
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Reclassification of lupus glomerulonephritis: back to the future. J Am Soc Nephrol (2004) 7.12
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet (2007) 5.93
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med (2005) 5.02
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int (2011) 4.51
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int (2013) 4.36
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med (2003) 4.35
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature (2012) 4.26
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet (2002) 4.22
Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis (2004) 4.20
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med (2011) 4.08
Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med (2010) 3.78
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Pathologic classification of diabetic nephropathy. J Am Soc Nephrol (2010) 3.61
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol (2010) 3.48
Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation (2002) 3.41
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis (2013) 3.39
Initiation of dialysis at higher GFRs: is the apparent rising tide of early dialysis harmful or helpful? Kidney Int (2009) 3.36
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood (2007) 3.27
Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol (2006) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
C3 glomerulopathy: a new classification. Nat Rev Nephrol (2010) 3.17
Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol (2003) 3.06
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int (2010) 2.95
Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int (2013) 2.87
Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1 in urine. Transplantation (2002) 2.86
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol (2012) 2.83
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet (2004) 2.82
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 2.72
Dissecting and refining the staging of chronic kidney disease. Kidney Int (2009) 2.72
Case records of the Massachusetts General Hospital. Case 31-2007. A 41-year-old man with abdominal pain and elevated serum creatinine. N Engl J Med (2007) 2.71
Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes (2005) 2.67
Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med (2012) 2.67
Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev (2009) 2.65
PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med (2011) 2.64
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol (2008) 2.64
Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure. N Engl J Med (2010) 2.62
Management of glomerular proteinuria: a commentary. J Am Soc Nephrol (2003) 2.59
Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol (2005) 2.58
Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2008) 2.57
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol (2004) 2.53